Market capitalization | $8.60b |
Enterprise Value | $8.96b |
P/E (TTM) P/E ratio | 106.33 |
EV/FCF (TTM) EV/FCF | 17.69 |
EV/Sales (TTM) EV/Sales | 4.53 |
P/S ratio (TTM) P/S ratio | 4.35 |
P/B ratio (TTM) P/B ratio | 2.39 |
Dividend yield | 3.44% |
Last dividend (FY24) | $1.36 |
As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.
23 Analysts have issued a QIAGEN NV forecast:
23 Analysts have issued a QIAGEN NV forecast:
Dec '24 |
+/-
%
|
||
Revenue | 1,978 1,978 |
1%
1%
|
|
Gross Profit | 1,253 1,253 |
2%
2%
|
|
EBITDA | 698 698 |
7%
7%
|
EBIT (Operating Income) EBIT | 495 495 |
11%
11%
|
Net Profit | 84 84 |
76%
76%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Head office | Netherlands |
CEO | Thierry Bernard |
Employees | 5,765 |
Founded | 1996 |
Website | www.qiagen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.